Escalation to Biologics After Methotrexate Among US Veterans With Rheumatoid Arthritis Grouped by Rural Versus Urban Areas
- PMID: 39467025
- DOI: 10.1002/acr.25457
Escalation to Biologics After Methotrexate Among US Veterans With Rheumatoid Arthritis Grouped by Rural Versus Urban Areas
Abstract
Objective: Racial and ethnic disparities in rheumatoid arthritis (RA) outcomes are well recognized. However, whether disparities in RA treatment selection and outcomes differ by urban versus rural residence, independent of race, have not been studied. Our objective was to evaluate whether biologic disease-modifying antirheumatic drug (bDMARD) initiation after methotrexate administration differs by rural versus urban residence among veterans with RA.
Methods: In this retrospective cohort study using national US Veterans Affairs (VA) databases, we identified adult patients with RA based on the presence of diagnostic codes and DMARD administration. We included patients receiving an initial prescription of methotrexate (index date) between 2005 and 2014, with data through 2016 used for follow-up. Urban-rural status was categorized using the Veteran Health Administration's Urban/Rural classification. Our primary outcome of interest was time to biologic initiation within two years of starting methotrexate. Multivariable Cox proportional hazards models were conducted adjusting for demographics, comorbidities, and rheumatoid factor or anti-cyclic citrullinated peptide positivity.
Results: Among 17,395 veterans with RA (88% male, 42% with rural residence) fulfilling eligibility criteria, 3,259 (19%) initiated a biologic within the first two years of follow-up. In multivariable models, residence in an urban area was associated with a statistically significant higher biologic administration compared to rural areas (adjusted hazard ratio 1.10 [95% confidence interval 1.02-1.18]).
Conclusion: Our study found only modest differences in the initiation of biologic therapies among rural- versus urban-residing veterans with RA in the VA health care system. These findings suggest that disparities are not easily explained by rurality within the VA health care system.
© 2024 American College of Rheumatology.
Similar articles
-
Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.J Manag Care Spec Pharm. 2019 Nov;25(11):1218-1228. doi: 10.18553/jmcp.2019.25.11.1218. J Manag Care Spec Pharm. 2019. PMID: 31663467 Free PMC article.
-
Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.Clin Ther. 2016 May;38(5):1205-16. doi: 10.1016/j.clinthera.2016.03.013. Epub 2016 Apr 2. Clin Ther. 2016. PMID: 27045991
-
Biologic and Glucocorticoid Use after Methotrexate Initiation in Patients with Rheumatoid Arthritis.J Rheumatol. 2019 Apr;46(4):343-350. doi: 10.3899/jrheum.180178. Epub 2018 Oct 1. J Rheumatol. 2019. PMID: 30275262 Free PMC article.
-
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657. Cochrane Database Syst Rev. 2017. PMID: 28481462 Free PMC article. Review.
-
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183. Cochrane Database Syst Rev. 2016. PMID: 27175934 Free PMC article. Review.
References
REFERENCES
-
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2021;73(7):924–939.
-
- Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2016;68(1):1–26.
-
- Greenberg JD, Spruill TM, Shan Y, et al. Racial and ethnic disparities in disease activity in patients with rheumatoid arthritis. Am J Med 2013;126(12):1089–1098.
-
- Barton JL, Trupin L, Schillinger D, et al. Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university‐affiliated clinics. Arthritis Care Res (Hoboken) 2011;63(9):1238–1246.
-
- Yip K, Navarro‐Millán I. Racial, ethnic, and healthcare disparities in rheumatoid arthritis. Curr Opin Rheumatol 2021;33(2):117–121.
Publication types
MeSH terms
Substances
Grants and funding
- HX003260/VA Health Systems Research
- R03-AG-082857/AG/NIA NIH HHS/United States
- Rheumatology Research Foundation Investigator award
- IK2-CX-002203/VA Clinical Science Research and Development
- BX003635/VA Biomedical Laboratory Research and Development
- IK2 CX002203/CX/CSRD VA/United States
- PR200793/United States Department of Defense
- U54-GM-115458/National Institute of General Medical Sciences, NIH
- R03 AG082857/AG/NIA NIH HHS/United States
- K23-AR-079588/AR/NIAMS NIH HHS/United States
- U54 GM115458/GM/NIGMS NIH HHS/United States
- Rheumatology Research Foundation
- HX003350/VA Health Systems Research
- P30-AG-022845/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical